Home > Financial Ratios > GLENMARK PHARMACEUTICALS

GLENMARK PHARMACEUTICALS
Core EBITDA Growth

    Back to All Ratios
AD     Remove this Ad

GLENMARK PHARMACEUTICALS Last 5 Year Core EBITDA Growth History

[Consolidated]

Mar2025Mar2024Mar2023Mar2022Mar2021
   Core EBITDA Growth(%) 21.125.79-22.6416.5114.91

What is the latest Core EBITDA Growth ratio of GLENMARK PHARMACEUTICALS ?

The latest Core EBITDA Growth ratio of GLENMARK PHARMACEUTICALS is 21.12 based on Mar2025 Consolidated results.
Year Core EBITDA Growth
Mar202521.12
Mar20245.79
Mar2023-22.64
Mar202216.51
Mar202114.91

How is Core EBITDA Growth of GLENMARK PHARMACEUTICALS Trending?

Years Core EBITDA Growth % Change
Mar2025 21.12
264.77
Mar2024 5.79
Positive
Mar2023 -22.64
Negative
Mar2022 16.51
10.73
Mar2021 14.91 -

Other Financial Ratios of GLENMARK PHARMACEUTICALS


Compare Core EBITDA Growth ratio of peers of GLENMARK PHARMACEUTICALS

Peers & Returns Market Capitalization 1 Week 1 Month 1 Year
GLENMARK PHARMACEUTICALS ₹61,037.0 Cr 2.8% 2.2% 40.6% Stock Analytics
SUN PHARMACEUTICAL INDUSTRIES ₹397,018.0 Cr -2.3% -8.5% -3% Stock Analytics
DIVIS LABORATORIES ₹162,454.0 Cr 5.3% -3.4% 3.4% Stock Analytics
TORRENT PHARMACEUTICALS ₹140,702.0 Cr 3.7% -4.9% 26% Stock Analytics
DR REDDYS LABORATORIES ₹102,830.0 Cr 1.2% -4.2% 5.3% Stock Analytics
CIPLA ₹99,325.0 Cr 2.4% -7.2% -18.1% Stock Analytics


GLENMARK PHARMACEUTICALS Share Price vs Sensex


Share Price Returns(%) 1 Week 1 Month 1 Year
GLENMARK PHARMACEUTICALS

2.8%

2.2%

40.6%

SENSEX

5.8%

-1.7%

1.2%


You may also like the below Video Courses